Skip To Main Content
Barbara Dema on Muck Rack

Barbara Dema

As seen in: Nature, MDPI
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara

Contact Barbara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Aerosol immunization with influenza matrix, nucleoprotein, or both prevents lung disease in pig - npj Vaccines

|
By Barbara Dema, Simon Gubbins, Ronan MacLoughlin
| Nature Verified
Abstract Current influenza vaccines are strain-specific and require frequent updates to combat new strains, making a broadly protective influenza vaccine (BPIV) highly desirable. A promising strategy is to induce T-cell responses against internal proteins conserved across influenza strains. In this study, pH1N1 pre-exposed pigs were immunized by aerosol using viral vectored vaccines (ChAdOx2 and MVA) expressing matrix (M1) and nucleoprotein (NP).
Open in Who Shared Issue with article?

Life | Free Full-Text | Plasmodium vivax MSP1-42 kD Variant Proteins Detected Naturally Induced IgG Antibodies in Patients Regardless of the Infecting Parasite Phenotype in Mesoamerica

|
By Lilia González-Cerón, Barbara Dema, Frida Santillán-Valenzuela, Olga L. Palomeque-Culebro
| MDPI
Font Type: Arial Georgia Verdana Line Spacing:    Column Width:    Open AccessArticle by Lilia Gonzalez-Ceron 1,*, Barbara Dema 2, Olga L.
Open in Who Shared Issue with article?

COVID-19 vaccines: breaking record times to first-in-human trials

|
By young kim, Barbara Dema, Arturo Reyes-Sandoval
| Nature Verified
The twenty-first century has come with a new era in vaccinology, in which recombinant genetic technology has contributed to setting an unprecedented fast pace in vaccine development, clearly demonstrated during the recent COVID-19 pandemic. COVID-19 is caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). As of 15th April 2020, the World Health Organization (WHO) has reported over 1.7 million cases of COVID-19 and 100,000 deaths worldwide1.
Open in Who Shared Issue with article?
See all 4 articles